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Abstract
To extend the understanding of host genetic determinants of HIV-1 control, we performed a genome-wide association study
in a cohort of 2,554 infected Caucasian subjects. The study was powered to detect common genetic variants explaining down
to 1.3% of the variability in viral load at set point. We provide overwhelming confirmation of three associations previously
reported in a genome-wide study and show further independent effects of both common and rare variants in the Major
Histocompatibility Complex region (MHC). We also examined the polymorphisms reported in previous candidate gene studies
and fail to support a role for any variant outside of the MHC or the chemokine receptor cluster on chromosome 3. In addition,
we evaluated functional variants, copy-number polymorphisms, epistatic interactions, and biological pathways. This study
thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians.
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Introduction
The clinical outcome of HIV-1 infection is highly variable and
determined by complex interactions between virus, host and
environment. Several human genetic factors have been reported to
modulate HIV-1 disease [1,2], but current knowledge only
explains a small fraction of the observed variability in the course
of infection. Our first genome-wide association study (GWAS) of
human genetic variants that associate with HIV-1 control
analyzed 486 individuals of European ancestry and identified
two genome-wide significant determinants of viremia at set point,
and one determinant of disease progression [3]. The 3 single
nucleotide polymorphisms (SNPs) collectively explained 14% of
the variation in viral load at set point and 10% of the variation in
disease progression. All 3 were located in the Major Histocom-
patibility Complex (MHC) region on chromosome 6, confirming,
in a genome-wide context, the essential role played by the MHC
region in HIV-1 control [4,5,6]. Since then, the findings have been
replicated by several independent groups that used either targeted
genotyping [7,8,9] or whole genome approaches [10,11].
The power of our initial study was limited to the detection of
common variants (with minor allele frequency of 5% or more)
which explain a sizable fraction of the phenotypic variability: it
had an 80% power of identifying SNPs that explain at least 5% of
the variability. Here we have increased the sample size to 2554
which allows us to provide a much more thorough investigation of
the role of common variation in the control of HIV-1: considering
the final number of participants included in the analysis, the study
was powered to detect the effects of common variants down to
1.3% of explained variability.
One surprising feature of the first genome-wide investigation
was that it failed to identify any of the many non-MHC candidate
gene variants that have been reported to associate with HIV-1
disease outcomes over the past 15 years. Candidate gene studies
claimed associations for variants in genes selected for their known
or suspected role in HIV-1 pathogenesis and in immune response
[1,2] [compiled in http://www.hiv-pharmacogenomics.org]. Col-
lectively, this body of work has implicated various components of
innate, adaptive, and intrinsic immunity in HIV-1 control, cellular
co-factors important in viral life cycle, and quite unexpected
candidates such as the vitamin D receptor. We here use our large
sample size and the power of genome-wide data, which allows
precise correction for population stratification, to evaluate most
candidate gene discoveries.
Genome-wide analysis also makes it possible to assess genetic
interactions, copy number polymorphisms, enrichment of gene
sets and of functional variants: these analyses were pursued in the
present work. Collectively, our study circumscribes the impact of
common variation in the control of HIV-1 in an adult and
predominantly male Caucasian population.
Results
Subjects
A total of 2554 HIV-1 infected individuals of self-reported
Caucasian ancestry were genotyped on Illumina whole-genome
chips (Table S1). Participants were recruited between 1984 and
2007 in one of the 9 cohorts forming the Euro-CHAVI
Consortium (N=1397, including 486 subjects that were included
in our previous study [3], 75.7% male, median age: 33 years) or in
the MACS cohort (N= 1157, 100% male, median age: 33 years).
A subset of 1113 patients had a proven date of seroconversion
(‘‘seroconverters’’) and the remainder had a confirmed stable
viremia profile but no known date of infection (‘‘seroprevalent’’
patients). Several quality control steps (Text S1) resulted in the
exclusion of 115 individuals with insufficient genotype call rates, of
17 individuals that were found to be genetically related with
another study subject, and of 5 individuals with a gender
discrepancy between phenotype and genotype data. To control
for population stratification, we performed a principal component
analysis of the whole-genome genotyping data (Eigenstrat [12],
Text S1), which identified 12 significant axes after exclusion of 55
outlier subjects. The most significant principal component is a
north-to-south European axis that has already been described [13]
(Figure S1). A total of 2362 individuals were included in the set
point association analyses (including 486 subjects studied before
[3]), and 1071 seroconverters were eligible for the analysis of
disease progression (including 337 subjects studied before [3]). A
subset of 1204 subjects had complete 4-digit HLA Class I results
and could be included in models assessing the respective influences
of SNPs and HLA alleles on HIV-1 control.
Common variants and variation in viral load at set point
All QC-passed SNPs (Text S1, Table S11) were tested for
association with HIV-1 viremia at set point in separate linear
regression models that included gender, age, and the 12 significant
PC axes as covariates. The global distribution of resulting p-values
was very close to the null expectation (l=1.006, Figure S2)
indicating that stratification was adequately controlled [14]. Male
gender and older age both associated with higher set point
(p = 1.9E-21 and p= 2.6E-05, respectively) and explained 4% of
the inter-individual variability. The population sub-structure,
reflected in the 12 significant PC axes, explained an additional
3.4%.
The 2 SNPs previously reported as genome-wide significant [3]
were confirmed to be the strongest determinants of variation in
HIV-1 viral load (Figure 1 and Figure 2): rs2395029, an HCP5
T.G variant, which is known to be an almost perfect proxy for
HLA-B*5701 in Caucasians [15,16] (p = 4.5E–35), and rs9264942,
a T.C SNP located in the 59 region of HLA-C, 35 kb away from
transcription initiation (p = 5.9E–32). Of note, the association
signals were also convincingly genome-wide significant in an
analysis restricted to the subjects that were not included in our
initial study (Table 1). Each SNP explained 5 to 6% of the
variability in set point viremia, as determined by the increase in
Author Summary
The ability to spontaneously control HIV-1 upon infection
is highly variable between individuals. To evaluate the
contribution of variation in human genes to differences in
plasma viral load and in disease progression rates, we
performed a genome-wide association study in .2,500
HIV–infected individuals. This study achieved two goals: it
completed the analysis of common variation influencing
viral control, and it re-assessed the majority of previously
reported genetic associations. We show that genetic
variants located near the HLA-B and HLA-C genes are the
strongest determinants of viral control, and that other
independent associations exist in the same region of
chromosome 6, the Major Histocompatibility Complex,
known to contain a large number of genes involved in
immune defense. We could not replicate most of the
previously published associations with HIV candidate
genes in this large, well-characterized cohort. Overall,
common human genetic variation, together with demo-
graphic variables, explains up to 22% of the variability in
viral load in the Caucasian population.
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the r2 value of the respective linear regression models: the effect
size estimates are smaller in the expanded data set than in the
previously reported study. This is due, at least in part, to the
inclusion of seroprevalent subjects with less stringent phenotype
definition. Interestingly, we observed a break in the strong linkage
disequilibrium (LD) between HCP5 and HLA-B in 9/1204 subjects
with HLA Class I results (0.7%, r2= 0.93): the set point values
were lower for the 4 patients that had B*5701 without the
rs2395029 minor allele than for the 5 patients with a G at
rs2395029 but without B*5701 (median [IQR] log10 HIV-1 cp/
ml = 3.14 [2.77–3.68] vs. 4.22 [4.14–4.28] respectively (Table
S2); p = 0.05, Kruskal-Wallis rank test). Consequently, the
association with set point was stronger for B*5701 (p= 3.8E–19)
than it was for rs2395029 (p = 1.7E–17) in the same subset of
patients.
A major challenge in assessing association evidence in the MHC
is the long range pattern of LD, complicating the definitive
identification of causal variants and making it necessary to
consider evidence for association in the region as a whole. For
this reason, we evaluated the evidence for independent effects of
the two reported associations. Since the HCP5 and the HLA-C
variants are in partial LD (r2 = 0.06, D9=0.86), the combined
strength of their associations with set point is less than the sum of
the signals measured separately. It is also interesting to note that in
95% of cases the rs2395029 minor allele, tagging B*5701, is found
in combination with the controlling C allele at HLA-C rs9264942.
This means that the protective effect in this haplotype is a
combination of the effect of both alleles and that analyses that are
not adjusted for the HLA-C variant overestimate the B*5701-
related effect. Nonetheless, nested regression models clearly
demonstrated that each of the variants is independently genome-
wide significant (p = 1.8E–23 for rs2395029; p= 2.4E–20 for
rs9264942). We therefore can conclude unequivocally that the two
SNPs represent independent effects: they together explain 9% of
the variability in HIV-1 set point.
Further independent associations in the MHC region
We next addressed the question of whether there are any
additional, independent and significant SNP effects in the MHC
region. In addition to the top 2 associated variants, 86 other SNPs
met the criteria of genome-wide significance (p,5E–08), all
located in the MHC (Figure 1, Table S9).
We included a total of 331 MHC SNPs with p,1E–04 in a
conservative forward selection algorithm within a linear regression
model. SNPs were tested and selected into the model one at a
time, independently of the top 2 associated variants and of the
other covariates (gender, age and Eigenstrat axes). In order to
control for multiple testing, a permutation procedure was
performed to assess the empirical significance cut-off value. Four
additional SNPs were found to significantly associate with set point
in models including the previously associated variants (Table S3):
[1] rs259919, located in an intron of the uncharacterized C6orf12
gene, 3.5 kb away from the ZNRD1 gene in the 59 region; [2]
rs9468692, located in the 39 region of the TRIM10 gene, in high
LD (r2 = 0.87) with a non-synonymous coding SNP in the first
exon of TRIM10 - rs12212092: 279A.G; H65R, which is
predicted to be a high-risk change by FastSNP [17] (non-
conservative amino acid change; possibly splicing regulation); [3]
rs9266409, located in the 39 region of HLA-B, 12 kb away; [4]
rs8192591, a non-synonymous coding SNP located in the 9th exon
of the NOTCH4 gene: 1739A.G; S534G (conservative amino acid
change; possibly influencing splicing). We emphasize that these
analyses demonstrate that there are further independent effects in
the MHC region, but they do not prove that the specific SNPs
implicated are responsible for those effects. Some or all of these
SNPs are most likely markers for one or more variants that have
Figure 1. Significant hits in the MHC region. Representation of a 3 Mb stretch in the MHC region, encompassing the HLA Class I gene loci and
the genome-wide significant SNPs identified in the study (red dots represents SNPs with p-value,5E–08). Results are shown for set point (upper plot)
and for progression (lower plot). The figure was created with WGAViewer [40].
doi:10.1371/journal.pgen.1000791.g001
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not been genotyped and which provide aspects of viral control
independent of the two previously reported associations.
As one possible contribution to these associations we assessed
the HLA Class I alleles in the subset of 1204 subjects who had full
MHC typing results. The 4-digit alleles were tested separately and
in models including the identified MHC SNPs (Table 2, Table S4).
15 alleles were found to associate with set point, but only 4 of them
(A*3201, B*1302, B*2705 and B*3502) had an independent effect
that was still detectable in models including the top associated
SNPs. Several HLA-C alleles associated significantly with viral
control before but not after adjustment for the top SNPs (Table 2,
Table S6). This is partly because all HLA-C alleles are in LD with
the HLA-C -35 rs9264942. They can in fact be perfectly divided
into 2 mutually exclusive groups on the basis of their LD with the
rs9264942 C or T allele. The C-related alleles, as a group, strongly
associated with lower setpoint (p = 2.8E–14) but failed to entirely
recapitulate the rs9264942 association signal (p = 8.4E–16 in this
group). Homozygosity for the HLA Class I loci also showed a weak
independent association (p = 0.03 after adjustment for the SNPs).
Altogether, a model including 6 SNPs, 4 alleles and homozygosity
status shows that MHC variation explains 12% of the set point
variability in this cohort.
HIV-1 disease progression
We defined HIV-1 disease progression as the drop of CD4 T
cell count to below 350 cells/ul or the initiation of potent
antiretroviral treatment (cART) following a CD4 T cell count
,500 cells/ul. A total of 1071 individuals with known date of
seroconversion and at least two CD4 T cell determinations in
absence of cART were included in a survival analysis. Of those,
765 (71.4%) progressed during follow-up: 612 (80%) because of a
CD4 T cell value ,350/ul and 153 (20%) because they started
treatment with ,500 CD4 T cells per ul.
The top associated variants were HCP5/B*5701 rs2395029
(p = 1.2E–11) and HLA-C rs9264942 (p= 6.4E–12) (Figure 1 and
Figure 3, Table S10). If viral load at set point is added to the
models, the association signals are much weaker (p = 0.001 for
rs2395029 and p= 0.02 for rs9264942), demonstrating that the
HCP5/B*5701 and HLA-C effects on disease progression are
mainly driven by their impact on early viral control. Another set of
variants reached genome-wide significance: rs9261174,
rs3869068, rs2074480, rs7758512, rs9261129, rs2301753 and
rs2074479 (p = 1.8E–08), in high-LD and located around the
ZNDR1 and RNF39 genes, close to the HLA-A locus in the MHC
region. This association is largely independent of viremia
(p = 4.7E–05 in a model including set point as covariate),
suggesting that a different mechanism of action is here modulating
HIV disease progression. The causal variant(s) responsible for this
association remains largely undetermined, and it seems possible
that the association depends on the contribution of multiple causal
sites. We do note, however, that no single HLA Class I allele can
account for the association. Specifically, the recent claim that it is
due entirely to the A10 serogroup of HLA-A alleles [7] is not
supported by the LD data. When this claim is evaluated by
including the A10 alleles in a regression model and testing the
significance of the increased variation explained by the ZNRD1
SNPs, we observe an independent additional effect of the SNPs
(p = 0.03). Indeed, the identified SNPs still associate with
progression in individuals without HLA-A10 (Figure S3). Con-
versely, HLA-A10 alleles do not significantly associate with
Figure 2. Correlation between HIV-1 set point and the
genotypes of the top associated SNPs. HIV-1 viremia at set point
strongly associates with rs2395029 (upper panel) and rs9264942 (lower
panel) genotypes. The rs2395029 minor allele G has a frequency of 4.8%
and each copy of this allele associates with a 0.7 log lower set point.
The rs9264942 minor allele C has a frequency of 41.2%, and each copy
of this allele associates with a 0.3 log lower set point. Mean and
Standard Deviation (error bars) are represented for the respective
genotypes.
doi:10.1371/journal.pgen.1000791.g002
Table 1. P-values and population effect sizes (or explained fraction of the inter-individual variability) for the strongest
determinants of HIV-1 viremia at set point.
SNP MAF Gene
P-value (initial,
N=486)
Effect Size
(initial)
P-value (replication,
N=1896)
Effect Size
(replication)
P-value (all,
N =2362) Effect Size (all)
rs2395029 4.8% HCP5/B*5701 9.4E–12 9.6% 4.2E–23 4.9% 4.5E–35 5.8%
rs9264942 41.2% HLA-C 3.8E–09 6.5% 1.6E–23 4.8% 5.9E–32 5.3%
Results are shown for the subjects that were included in our initial study [3] (initial), for the subset of subjects that are new to the present study (replication), and for the
global study population (all). MAF: Minor allele frequency.
doi:10.1371/journal.pgen.1000791.t001
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progression in models that include the ZNRD1 SNPs. The fact that
A10 alleles (notably A*2501 and A*2601) are in LD with the
ZNRD1 SNPs (r2 = 0.46) is not sufficient evidence to assign
responsibility for the association, although A10 may contribute to
the association signal.
Genetic variants in HIV candidate genes
We tested a total of 34 SNPs in 21 genes, representing 27 previously
reported associations with HIV-1 control (individual SNPs or
haplotypes) (Table 3) [1,2,18]. Nine SNPs were directly genotyped
and 12 had a good proxy (r2.0.8) on all the chips that we used. Two
were present on the Human1M chips only and 9 were not represented:
these 11 SNPs were genotyped by TaqMan assays. The CCL3L1 copy
number polymorphism was also assessed and the absence of any
association with HIV-1 control has been recently reported [19].
The CCR5-D32 variant, a 32 bp deletion in the main HIV-1 co-
receptor that protects against HIV-1 acquisition when present in
homozygous form [20,21,22], strongly associated with both set point
(p= 1.7E–10) and progression (p=3.5E–07). CCR5-D32 explained
1.7% of the variability in viral control. Only two other variants
showed significant associations: The CCR5 promoter variant P1 [23],
found on a haplotype known to increase CCR5 expression [24],
associated with higher set point and faster progression, whereas the
CCR2-64I variant, a Valine to Isoleucine change in the HIV-1 minor
receptor CCR2 [25,26] associated with better viral control (Table 3).
They together explained 1% of the variability in viral control. Partial
association results for the two CCR5 variants in a subset of our study
population were reported elsewhere [19].
Effect of identified genetic determinants throughout the
full phenotype range
By design, this study focused on the control of HIV-1 as a
quantitative trait, with a particular focus on the amount of virus
during the set point period. One important question to address
therefore is whether the genetic determinants identified influence
viral control throughout the full phenotypic range, from those with
low to high viral loads, and from slow to fast progression times. To
address this, we looked at allele frequencies in individuals that
maintained variable degrees of viral control: we found a consistent
enrichment of the protective alleles in categories of subjects with
good viral control or slow disease progression rate in comparison
to subjects with poor control or rapid progression (Figure 4).
Additional analyses
The large genotypic and phenotypic data set generated in this
study is a resource that allows a more in-depth exploration of the
role of human genetic variation: we ran additional analyses to test
whether there is any evidence from the existing data, which mainly
represents common variants, for other determinants of viral control.
We first performed a genome-wide screen (Text S1) for SNPs
that modify the effect of rs2395029 (HCP5/B*5701), rs9264942
(HLA-C) rs9261174 (ZNRD1/RNF39) and CCR5-D32: no interac-
tion was large enough to reach genome-wide significance. To
evaluate common structural variation, we tested 285 SNPs that
were identified as tags for copy number polymorphisms (CNP) in
HapMap CEU samples [27]. No significant association was
observed when theses CNP-tagging SNPs were considered as a set.
We also used a gene set enrichment analysis (GSEA) [28,29] to ask
whether groups of genes or pathways were enriched in SNPs with
low association p-values: 5 gene sets were significant, some of them
with suggestive evidence of involvement in HIV-1 pathogenesis
(Table S7). Finally, we developed a permutation procedure to test
whether genetic variants with known functional role were more
likely to associate with differences in HIV-1 control than non-
functional SNPs: we observed a significant effect that was however
limited to the MHC region (p = 0.001) (Figure S4).
Table 2. Associations between 4-digit HLA Class I alleles and HIV-1 set point in a subset of 1,204 subjects with full results.
HLA Allele
Model with HLA allele
only
Model with HLA allele,
rs2395029
Model with HLA allele,
rs2395029, rs9264942
Model with HLA allele, rs2395029,
rs9264942, rs259919, rs9468692,
rs9266409, rs8192591 Effect
A*2402 3.4E–02 6.9E–02 1.1E–01 9.9E–01
A*2501 2.8E–02 2.7E–02 1.2E–01 3.2E–01
A*3201 5.0E–03 1.0E–03 6.0E–03 2.9E–02 protective
B*0702 7.0E–03 1.5E–02 4.3E–01 3.8E–01
B*0801 7.0E–03 3.3E–02 5.8E–01 2.4E–01
B*1302 2.0E–03 2.1E–04 1.2E–02 1.6E–02 protective
B*2705 5.2E–05 4.9E–06 2.0E–03 3.0E–03 protective
B*3502 1.9E–05 3.9E–05 6.2E–04 2.0E–03 deleterious
B*5601 4.2E–02 7.8E–02 1.9E–01 1.2E–01
C*0202 1.0E–03 2.5E–04 6.0E–02 5.0E–02
C*0401 5.0E–03 3.0E–02 9.3E–01 8.5E–01
C*0602 1.2E–11 4.9E–02 7.1E–01 7.8E–01
C*0701 5.4E–04 3.0E–03 1.8E–01 7.8E–01
C*0702 3.4E–02 6.3E–02 9.9E–01 9.5E–01
C*0802 1.2E–02 2.0E–03 1.6E–01 2.5E–01
P-values are shown for all Class I alleles that have a nominally significant association with HIV-1 viral load at set point (with the exception of B*5701, discussed in the
text). All linear regression models include gender, age and the 12 Eigenstrat axes as covariates. Most of the association signals disappear once the top associated SNPs
are added. However, A*3201, B*1302, B*2705 and B*3502 still have an independent effect. See Table S4 for a complete list of all HLA Class I allele results. In addition,
Table S5 lists all pairs of HLA-B and HLA-C alleles that are in LD (with an r2.0.1) and therefore can represent the same association signal (as for example in the case of
HLA-C*0602, which is often on the same haplotype as HLA-B*5701).
doi:10.1371/journal.pgen.1000791.t002
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Discussion
The results presented here reaffirm the central role of the MHC
in HIV-1 control by first confirming with certainty the
independence of two association signals in the genomic region
that encompasses HLA-B and HLA-C. These common variants
show the strongest association with both viral set point and
progression. We initially speculated that the HCP5 gene itself,
which contains the top-associated SNP rs2395029, contributes to
HIV-1 control [3], but recent epidemiologic and functional reports
[30,31,32] suggest that the gene and the variant itself have no such
effect. In addition, we here present data from a small number of
subjects with a recombination event between HCP5 and HLA-B
indicating that HLA-B*5701 is the main contributor to the
association signal: the HCP5 variant is therefore likely to be only a
marker for the effect of HLA-B*5701 and possibly of other
protective variants present on the same haplotype. The HLA-C
variant rs9264942, which is in partial LD with all HLA-C alleles
(Table S6), associates with mRNA and protein expression levels of
HLA-C [3,33] (R. Thomas, M.C., personal communication): it is
thus likely that this SNP is in fact a marker of the effect of HLA-C
expression on HIV-1 control: more work is needed to understand
the precise immunological and biological function of HLA-C in
the context of HIV-1 infection.
Beyond the top 2 associated variants, we demonstrate that there
are other, independent, genetic contributors to HIV-1 control in the
MHC. The intricacy of the LD pattern in the region makes it difficult
to find causal variants with certainty. Nevertheless, using both SNP
and HLA Class I data, we identify additional variants that associate
independently with viral set point and together explain at least 3.5%
of the variability, on top of the 9% explained by the first 2 SNPs. We
do not know at this stage whether any of the 4 SNPs identified in our
permutation analysis have a direct functional role, though a non-
synonymous coding change in a TRIM gene represents an attractive
candidate [34]. Several of the HLA alleles that independently
associate with control have good functional support for their
involvement in HIV-1 pathogenesis: B*2705 presents epitopes that
lead to efficient viral restriction [35], while B*3502 is a member of the
B35Px group [36] that, according to recent data obtained on B*3503,
has a preferential binding to the inhibitory myelomonocytic MHC
class I receptor ILT4 on myeloid dendritic cells, which results in
dysfunctional antigen-presenting properties of these cells (XG Yu,
personal communication). Functional studies of the gene variants
identified in the MHC and deeper understanding of the structure of
the associations between SNPs and surrounding HLA alleles [16] are
warranted.
We show data that question most previously reported
associations in HIV-1 candidate genes (Table 3 and [19]). The
chemokine/chemokine receptor locus on chromosome 3 is the
only non-MHC region with convincing association evidence for an
impact of genetic variation on HIV-1 phenotypes. Homozygosity
for CCR5D32 is known to confer almost complete protection
Figure 3. Kaplan-Meier survival estimates for the top associated variants. Results are shown for the 3 most associated SNPs indentified in
the genome-wide progression scan and for CCR5-D32. The survival curves show, for each genotype, the proportion of the individuals that do not
reach a progression outcome over the first 10 years after seroconversion.
doi:10.1371/journal.pgen.1000791.g003
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against infection [20,21,22] and we here show that heterozygosity
for the 32 bp deletion is the strongest protective factor for VL
control and progression outside of MHC. While it is possible that
our analyses missed some real candidate gene associations, our
failure to replicate most previous reports confirms the critical
importance of adopting stringent standards for significance level
and stratification control [14,37,38].
Our study was powered to detect a single marker association
that explains just above 1% of the inter-individual variability in
HIV-1 control. In the absence of further significant association at
the individual SNP level, we sought to comprehensively assess the
impact of common variation by using the genotyping results in
several additional ways: these analyses provide no evidence for
strong interactions between the MHC or CCR5 polymorphisms
and any other common variant, or for CNP-related effects. We
also used a more global approach that shows enrichment for
associated variants in some interesting gene sets, but was not
designed to identify novel genetic determinants. Limitations to
Table 3. Variants in HIV-1 candidate genes, previously reported to associate with viral control or disease progression.
group SNP gene variant genotyping proxy r2 model
p
setpoint N
p
progression N effect
Chemokine
receptors
rs333 CCR5 delta 32 TaqMan no dominant 1.7E–10 2333 3.5E–07 1054 protective
rs1799988 CCR5 P1 - 627T.C TaqMan no recessive 7.5E–05 1791 3.8E–04 1012 deleterious
rs1799864 CCR2 V64I TaqMan no dominant 8.1E–03 2317 1.5E–01 1056 protective
rs3732378 CX3CR1 T280M present on all chips - recessive 1.5E–01 2362 6.0E–01 1071
Chemokines rs1719134 CCL3/MIP1a intron 459C.T proxy on all chips rs1634508 1 dominant 6.0E–01 2362 8.2E–01 1071
rs2107538 CCL5/RANTES promoter -403G.A proxy on all chips rs2291299 1 haplotypes
R1-R5:
additive
2.9E–01 2362 2.3E–01 1069
rs2280788 promoter -28C.G proxy on all chips rs4251739 1
rs2280789 In1.1 T.C proxy on all chips rs2306630 1
rs1801157 SDF-1/CXCL12 SDF-1 39A proxy on all chips rs10900029 1 recessive 8.6E–01 2362 9.2E–01 1071
Cytokines rs2243250 IL-4 promoter -589C.T proxy on all chips rs2243290 1 additive 3.4E–01 2362 6.3E–01 1065
rs1800872 IL-10 promoter -592C.A proxy on all chips rs3024490 1 dominant 6.5E–02 2362 1.4E–01 1065
rs1799946 DEFB1 promoter -52G.A proxy on all chips rs2741127 0.9 recessive 1.9E–01 1830 2.5E–01 931
Intracellular life
cycle
rs8177826 PPIA promoter 1604C.G TaqMan no dominant 6.0E–01 1808 6.3E–01 1065
rs6850 promoter 1650A.G TaqMan no dominant 7.7E–01 1753 1.4E–01 1065
rs2292179 TSG101 promoter -183T.C proxy on all chips rs3781640 1 haplotypes 7.9E–01 1792 1.9E–01 929
rs1395319 intron 181A.C TaqMan no
Intrisic immunity rs8177832 APOBEC3G NS coding H186R present on all chips - additive 3.2E–01 2362 5.2E–01 1071
rs3740996 TRIM5a NS coding H43Y present on all chips - recessive 7.3E–01 2362 9.3E–01 1071
rs10838525 NS coding R136Q present on all chips - additive 9.0E–01 2362 8.3E–01 1071
Innate immunity rs2287886 DC-SIGN/CD209 promoter -139T.C present on all chips - additive 9.2E–01 2362 1.2E–01 1065
rs5030737 MBL2 NS coding R52C 1M chip + TaqMan no recessive 4.5E–01 1735 2.9E–01 503
rs1800450 NS coding G54D present on all chips - recessive 4.3E–01 2361 9.0E–01 1064
rs1800451 NS coding G57E 1M chip + TaqMan no recessive 5.5E–01 1728 8.5E–01 501
rs352139 TLR9 intron 1174G.A proxy on all chips rs352163 0.9 additive 6.5E–01 2362 7.9E–01 1065
rs352140 syn coding P545P proxy on all chips 0.9
rs3764880 TLR8 NS coding V1M present on all chips - additive 5.0E–01 2361 9.3E–01 1064
Others rs601338 FUT2 W154stop proxy on all chips rs504963 0.8 dominant 1.1E–01 2362 7.0E–02 1065
rs1801274 FCGR2A NS coding H131R present on all chips - recessive 7.9E–01 2360 2.0E–01 1065
rs1544410 VDR intron 8 variant present on all chips - recessive 5.1E–01 2360 6.0E–01 1064
See http://www.hiv-pharmacogenomics.org/pdf/ref_tbl_nat_history/The_complete_reference_table_for_HIV_natural_history_modifiers.pdf for references. Dominant or
additive genetic models were used in the analyses for individual SNPs on the basis of their described effect and/or their minor allele frequencies. The P1 variant in the
CCR5 promoter region is defined by the SNP rs1799988 (627 C.T). Haplotypes R1 to R5 in the CCL5 (RANTES) gene were defined using 2 promoter variants (2403C.G,
defining haplotype R1, and228C.G, defining haplotype R5), and 1 intronic variant (375T.C, or In1.1, present in haplotypes R3, R4 and R5). The haplotype R4 is defined
by a2222T.C SNP that is monomorphic in Caucasians and was therefore absent in our study population. A combined variable was then defined and tested in additive
models: 0 = putatively deleterious haplotypes (presence of an R3 haplotype in the absence of R1 and R5), 1 = neutral haplotypes (all other) and 2 = haplotypes
putatively protective (presence of an R1 or R5 haplotype in the absence of R3). For the TSG101 gene, 2 SNPs defined haplotype B (2183T/181C), haplotype C (2183C/
181C) and haplotype A (2183T/181A). Again, a combined variable was defined and tested in additive models: 0 = haplotypes putatively deleterious (AC or CC),
1 = neutral haplotypes (AA or BC) and 2= haplotypes putatively protective (AB or BB). Only variants from the chromosome 3 CCR5-CCR2 genomic region showed
nominally significant association with the HIV-1-related outcomes under study. SNP: single nucleotide polymorphism. proxy: high-LD SNP (r2.0.8) that can be used as a
tag for the original variant. r2: r-squared. p: p-value.
doi:10.1371/journal.pgen.1000791.t003
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Figure 4. Allelic distribution of the significant variants in subsets of the study population. The bar graphs show the allelic distribution of
the 4 variants that have a genome-wide significant association with HIV-1 set point and/or disease progression in subsets of the study population.
Groups were defined according to HIV-1 set point (left-hand side graphs) and to progression time (right-hand side graphs).
doi:10.1371/journal.pgen.1000791.g004
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these additional analyses include [1] the deliberately limited scope
of our interaction screen, in which only pairs of SNPs including
one that is significant have been tested (Text S1): we did not run
any exhaustive SNP by SNP or haplotype analyses; [2] the use of
SNP tags for copy number assessment, which limits the analysis to
previously described deletions and duplications that are in LD with
common SNPs.
All variants securely identified in this study together explain
13% of the observed variability in HIV-1 viremia in a population
of mostly male Caucasian adults. The addition of gender, age and
residual population structure to the genetic model pushes this
figure up to 22%. These fractions compare favorably to what is
known for other complex traits, where dozens of SNPs often
explain only a few percent of the variance. Comparable studies are
certainly needed in additional populations, notably in other ethnic
groups, in women and in children to fully assess the impact of
common human genetic variation in HIV-1 control.
Many factors certainly contribute to the large unexplained
portion of the inter-individual variability (viral genetics/fitness,
environment, stochastic biological variation, noise in phenotype
determination), but it is also expected that much more is
attributable to human genetic variation. The data presented here
suggest that common polymorphisms are unlikely to add much,
unless more complex gene by gene and gene-environment
interactions play a major role in the genetic architecture of
HIV-1 control. After an era of candidate genes studies and a first
wave of large-scale genomics projects that could only interrogate
common genetic variation, resequencing strategies to identify rare
causal variants, as well as integration of multiple genome-level
data (genomic DNA, epigenetic marks, transcriptome, siRNA
screens) will prove essential to better appreciate the global
contribution of the human genome to HIV-1 control.
Methods
Ethics statement
All participating centers provided local institutional review
board approval for genetic analysis, and each participant provided
informed consent for genetic testing.
Patients/cohorts
Patients have been included from two sources (Text S1): [1]
Euro-CHAVI, a Consortium of 8 European and 1 Australian
Cohorts/Studies; and [2] MACS, the Multicenter AIDS Cohort
Study that enrolled homosexual and bisexual men in 4 US cities.
In general, patients had viral load (VL) and CD4 count monitoring
at least 6 monthly. Eligible patients had 3 or more stable plasma
HIV RNA results in the absence of antiretroviral treatment, and
met one of the following criteria: a valid seroconversion date
estimation proven by documents or biological markers; or, for
seroprevalent patients, VL data over a period of at least 3 years,
diverging by no more than 0.5 log. Only individuals with known
date of seroconversion and at least 2 CD4 T cell determinations in
absence of potent antiretroviral treatment (cART) were included
in the progression analysis.
Determination of phenotypes
HIV-1 set point was defined as the average of the remaining VL
results after careful assessment of each individual data and
elimination of VL outliers: see Text S1 for criteria used to identify
and exclude outlier VL data. Of note, our phenotype definition leads
to the exclusion rapid progressors that never reach a stable VL
plateau. The disease progression phenotype was defined as [1] the
drop of CD4 T cells below 350/ul, or [2] the initiation of cART, but
only if the last CD4 T cell count before cART start was ,500/ul.
This later criterion was made necessary by the different rationales
behind treatment initiation between patients and over time: a large
part of patients starting cART with CD4 T cell counts approaching
the 350/ul threshold did so because their CD4 slope actually showed
a significant decrease, whereas most of patients who started treatment
with normal or subnormal CD4 T cell counts had stable CD4 T cell
profiles. Since progression has been represented in a number of
different ways in genetic studies, we used the known genetic
determinants to confirm that our measure is the most accurate, by
comparing it to survival analyses that used cART start either as a
censoring event (i.e. all patients starting cART are considered non-
progressors) or as a progression event (i.e. all patients starting cART
are considered progressors) (Table S8).
Genotyping
All participants were genotyped using Illumina BeadChips: We
used HumanHap550 Beadchips for 1633 samples and Human1M
Beadchips for 921 samples. Most common SNPs found in the
HapMap CEU population are readily covered by both chips;
however, it is not clear yet whether common variants that have not
been genotyped in the HapMap project will be measured equally
well. To increase the coverage of the MHC region in the samples
genotyped with the 550K chip, we designed a customized MHC-
chip that contained an additional 8000 SNPs, largely overlapping
with the variants that are present on the Human1M chip. We
carried out a series of data cleaning and quality control
procedures: SNPs were filtered based on missingness (drop if call
rate ,99%), MAF (drop if ,0.006) and Hardy-Weinberg
Equilibrium deviation. Participants were filtered based on call
rate, gender check (heterozygosity testing), cryptic relatedness and
population structure (see EIGENSTRAT below). The genetic
variants located in HIV-1 candidate genes that were not
represented directly or indirectly on the genome-wide chips were
independently genotyped with TaqMan assays.
Gender check
The quality control of the genotyping data included a check on
the gender specification obtained from the phenotype database,
using the observed genotypes of SNPs on chromosome X and Y.
Subjects that were identified as ‘‘male’’ in the phenotype file but
had a significant amount of heterozygous X genotypes (.=1%),
as well as subjects that was identified as ‘‘female’’ in the phenotype
file but had a high frequency of homozygous X genotypes
(.=80%) and Y genotype readings were excluded.
Control for population stratification
To control for the possibility of spurious associations resulting
from population stratification we used a modified EIGENSTRAT
approach. This method derives the principal components of the
correlations among gene variants and corrects for those correla-
tions in the association tests. In principle therefore the principal
components in the analyses should reflect population ancestry.
Having noticed however that some of the leading axes depend on
other sources of correlation, such as sets of variants near one
another that show extended association (LD), we inspected the
SNP loadings and followed a series of pruning procedures to
ensure that EIGENSTRAT axes reflected only effects that applied
equally across the whole genome (Text S1).
Genome-wide association analysis
The core association analyses on HIV-1 setpoint focused on
single-marker genotype-trend tests of the quality control–passed
Human Genetic Variation and HIV Control
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SNPs using linear regression and including age, gender, and the
significant EIGENSTRAT axes values as covariates. Associations
with progression were tested using a Cox proportional hazards
model. We assessed significance with a Bonferroni correction
taking into account 1 million tests (p-value cutoff = 5E–08).
Search for independent associations in the MHC
To search for additional SNPs effects in the MHC region we used
a forward selection algorithm to investigate all MHC SNPs with
p,1E–04 (N=331). The top 2 associated variants and the standard
covariates were fixed in a linear regression model, while new SNPs
were added and selected into the model one at a time. In the
forward selection process, a newly selected SNP is expected to
explain a certain proportion of the set point variation independently
of all variables already in the model. To control for multiple testing,
a permutation procedure was used to assess the empirical
significance cut-off value. In the permutation, the LD patterns
among SNPs were retained while the associations between SNPs
and set point were permuted. 1000 permutation runs were
performed and the 5th percentile of the empirical distributions of
the partial R-squares and the p-values of the 1st, 2nd, 3rd, etc.
selected SNPs were recorded and compared to the observed sample
statistics. The permutation p-value was defined as the probability
that the statistics observed in the permutation was more extreme
than the statistics observed in the real sample. The forward selection
algorithm is expected to be conservative. To verify this, a large-scale
statistical simulation was performed, considering different effect
sizes, various LD patterns among SNPs and different sample sizes
(Text S1). The simulation results confirmed that the forward
selection algorithm with permutation procedure is conservative.
Interaction analysis
We performed a two-way interaction test between each QC-
passed SNP and the top associated variants. For each genome-
wide significant polymorphism, the screening procedure involved
the calculation of the p-value associated with each of the ,1
million multivariate linear models incorporating the 2 polymor-
phisms. The p-value associated with the interaction term for this
model was retained and then the top p-values for all ,1 million
tests considered. This approach followed recommendations that
the search space for interactions can be appropriately reduced and
therefore the power can be improved by focusing the search on
pairs of polymorphisms including at least one that is known to be
significant [39].
Gene set enrichment analysis (GSEA)
The SNPs that were represented in all genotyping chips were
mapped to their closest gene (if ,500 kb away) and used in the
GSEA analysis if minor allele frequency was .0.05, Hardy-
Weinberg Equilibrium test p-value was .0.001, and at least 90%
individuals were successfully genotyped. Among the 639 canonical
pathway gene sets that are represented in the Molecular
Signatures Database (MsigDB, http://www.broad.mit.edu/gsea/
msigdb/collections.jsp), we tested the 298 gene sets that had at
least 20 and at most 200 genes represented in the study (Text S1).
Functional variants
A permutation procedure was developed to test whether genetic
variants with known functional role were more likely to have a
lower p-values distribution than supposedly neutral variants (Text
S1). We compared the overall p-value distribution of 12,535
putatively functional polymorphisms, including stop-gained, stop-
lost, frame-shift coding, non-synonymous coding, and essential
splicing site genetic variants, with the global distribution of p-
values of all genotyped SNPs (with 10,000 permutations). We also
ran the same analysis for the MHC region only (318 functional
variants) and for the rest of the genome (12217 functional
variants).
Supporting Information
Figure S1 Distribution of individual eigen values along the first
axis identified by principal component analysis of the genotyping
data (Eigenstrat). Participants are grouped by country of
recruitment. The most important contributor to population
stratification in our Caucasian population is a North-to-South
European ancestry axis. Participants from the USA and Australia
are most similar to northern Europeans.
Found at: doi:10.1371/journal.pgen.1000791.s001 (0.05 MB
DOC)
Figure S2 QQ-plot of observed versus expected -log(p-values)
for all SNPs in the set point association analysis. The plot shows no
deviation from the expected line, except for the top 3000 SNPs
(0.3%).
Found at: doi:10.1371/journal.pgen.1000791.s002 (0.03 MB
DOC)
Figure S3 Associations between the SNPs identified in the
ZNRD1/RNF39 region and disease progression in individuals with
and without HLA-A alleles belonging to the serogroup A10. The
rs9261174 minor allele C shows the strongest association with
progression in individuals that also have an HLA-A10 (green), but
it also associates when HLA-A10 is absent (red). The LD (r2)
between the ZNRD1 SNP rs9261174 and HLA-A10 as a group is
0.46. It is 0.17 for HLA-A*2501, 0.25 for A*2601, 0.00 for A*3402
and 0.02 for A*6601.
Found at: doi:10.1371/journal.pgen.1000791.s003 (0.06 MB
DOC)
Figure S4 P-value distribution of functional variants. P-value
distributions of 12,535 functional genetic variants (red, A) in
comparison with 12,535 randomly selected intergenic variants
(red, B), both in the background of p-value distributions generated
from 10,000 permutations (blue, A and B). The upper figures show
the distributions of ranked -log10(P) for each of the observed and
permutated p-value series. The lower figures show the distribu-
tions of the sum -log10(P) generated from the permutated series
(blue), their 95% cutoff of empirical probability (cyan), and the
relative position and probability of the observed sum -log10(P)
(red) in these distributions. The sum -log10(P) from the observed
functional genetic variants (red, A) is higher than what would be
expected if there were no enrichment of low p-values in this series,
and this phenomenon is very unlikely to be due to chance
(p = 0.004), while the data from randomly selected 12,535
intergenic variants shows no difference (p = 0.76). The randomly
selected 12,535 intergenic variant series in (B) can be approxi-
mately viewed as one of the permutated data series in (A) except
that they are restricted to be annotated as intergenic, and is
presented here for better illustration of the results. Functional
genetic variants are those annotated as falling into one or more of
these categories: stop-gained, stop-lost, fame-shift coding, non-
synonymous coding, and essential splicing site genetic variants.
Ensembl database version 50_36i was used for these annotations.
Found at: doi:10.1371/journal.pgen.1000791.s004 (0.13 MB
DOC)
Table S1 Participants included in the study.
Found at: doi:10.1371/journal.pgen.1000791.s005 (0.04 MB
DOC)
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Table S2 VL setpoint values for groups of individuals with or
without a recombination event between HCP5 and HLA-B.
Found at: doi:10.1371/journal.pgen.1000791.s006 (0.03 MB
DOC)
Table S3 Results of the stepwise forward selection of MHC
SNPs.
Found at: doi:10.1371/journal.pgen.1000791.s007 (0.04 MB
DOC)
Table S4 Associations between 4-digit HLA Class I alleles and
HIV-1 set point in the subset of 1204 subjects with complete SNP
and HLA typing results.
Found at: doi:10.1371/journal.pgen.1000791.s008 (0.10 MB
DOC)
Table S5 Pairs of HLA-B and HLA-C alleles that are in linkage
disequilibrium (with an r2 of at least 0.1) in the subset of 1204
individuals with complete HLA typing results.
Found at: doi:10.1371/journal.pgen.1000791.s009 (0.07 MB
DOC)
Table S6 Associations betweenHLA-C alleles andHIV-1 set point in
the subset of 1204 subjects with complete SNP andHLA typing results.
Found at: doi:10.1371/journal.pgen.1000791.s010 (0.06 MB
DOC)
Table S7 Results of the GSEA analysis.
Found at: doi:10.1371/journal.pgen.1000791.s011 (0.04 MB
DOC)
Table S8 Comparison of the strength of the association results
for polymorphisms with clear association with HIV outcomes
using different definitions of progression in survival analyses.
Found at: doi:10.1371/journal.pgen.1000791.s012 (0.03 MB
DOC)
Table S9 Top 500 SNPs in the setpoint analysis.
Found at: doi:10.1371/journal.pgen.1000791.s013 (0.74 MB
DOC)
Table S10 Top 500 SNPs in the progression analysis.
Found at: doi:10.1371/journal.pgen.1000791.s014 (0.72 MB
DOC)
Table S11 Number of SNPs discarded during quality control
procedures.
Found at: doi:10.1371/journal.pgen.1000791.s015 (0.03 MB
DOC)
Text S1 Supplementary text.
Found at: doi:10.1371/journal.pgen.1000791.s016 (0.09 MB
DOC)
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